| Diabetes Mellitus, Non-Insulin-Dependent

Mounjaro vs Onglyza

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Mounjaro vs Onglyza with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsOnglyza has a higher rate of injection site reactions vs Mounjaro based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Onglyza but not Mounjaro, including UnitedHealthcare

Category

Mounjaro

Onglyza

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGIP/GLP-1 receptor agonist

RouteOral

FrequencyDaily

ClassDPP-4 inhibitor

Indications

Diabetes Mellitus, Non-Insulin-Dependent

Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Diabetes Mellitus, Non-Insulin-Dependent Start at 2.5 mg SC once weekly; increase to 5 mg after 4 weeks; escalate in 2.5 mg increments every >=4 weeks as needed; max 15 mg once weekly in adults and 10 mg once weekly in pediatric patients 10 years of age and older.

Diabetes Mellitus, Non-Insulin-Dependent 2.5 mg or 5 mg orally once daily taken regardless of meals; reduce to 2.5 mg once daily for eGFR <45 mL/min/1.73 m2 or when coadministered with strong CYP3A4/5 inhibitors.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known serious hypersensitivity to tirzepatide or any excipient in MOUNJARO

History of serious hypersensitivity reaction to saxagliptin or any ingredient in ONGLYZA (anaphylaxis, angioedema, or exfoliative skin conditions)

Drug Interactions

299View drug interactions

1202View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain

Serious Risk of thyroid C-cell tumors, acute pancreatitis, hypoglycemia (with insulin secretagogues or insulin), hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, diabetic retinopathy complications, acute gallbladder disease, pulmonary aspiration

Postmarketing Anaphylaxis, angioedema, acute pancreatitis, hemorrhagic and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, pulmonary aspiration, acute renal failure or worsening of chronic renal failure, alopecia

Most common (>=5%) Upper respiratory tract infection, urinary tract infection, headache

Serious Pancreatitis, heart failure, hypoglycemia with insulin or insulin secretagogues, hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid

Postmarketing Pancreatitis, anaphylaxis, angioedema, exfoliative skin conditions, rhabdomyolysis, severe and disabling arthralgia, bullous pemphigoid

Pharmacology

Tirzepatide is a dual GIP and GLP-1 receptor agonist that selectively binds and activates both receptors, enhancing first- and second-phase insulin secretion and reducing glucagon levels in a glucose-dependent manner, thereby lowering fasting and postprandial glucose, decreasing food intake, and reducing body weight.

Saxagliptin is a competitive DPP-4 inhibitor that slows the inactivation of incretin hormones (GLP-1 and GIP), increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Mounjaro